Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacology and preclinical animal models with no original clinical trial data.
PubMed 9222275 · doi:10.1212/wnl.49.1_suppl_1.s58
What was done
This narrative review summarizes the pharmacological profile and preclinical evidence for ropinirole, a nonergoline dopamine agonist evaluated for Parkinson's disease therapy.
What was found
The abstract reports that ropinirole selectively binds to D2-like dopamine receptors with an affinity rank order of D3 > D2 > D4. It notes efficacy across two standard preclinical models of Parkinson's disease and reports a low propensity to induce dyskinesias in these animal studies. No specific quantitative binding affinities, effect sizes, or numerical data are provided in the abstract.
Why it matters
Nonergoline dopamine agonists provide dopaminergic stimulation while avoiding the ergot-related adverse effects associated with older dopamine agonists, offering a strategy to spare levodopa and manage motor complications.
Limits
The abstract describes preclinical and narrative review data without presenting quantitative metrics, sample sizes, or original human clinical outcome data.
Cited by
- supports Ropinirole acts as a direct agonist at dopamine D2 and D3 receptors, in contrast to levodopa, which acts as a biochemical precursor for dopamine synthesis.